STIM Neuronetics, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1227636 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY23.0%
TTM net income YoY48.1%
TTM EPS YoY61.4%
Revenue 3-yr CAGR32.1%
Net income 3-yr CAGR—
Margins
Gross margin50.7%
Operating margin-9.4%
Net margin-14.4%
FCF margin-6.0%
EBITDA margin-8.0%
Returns
ROE-100.2%
ROA-16.6%
ROIC (approx.)-19.2%
Asset turnover1.15x
Leverage & solvency
Liabilities / assets83.0%
Debt / equity3.30x
Current ratio2.01x
Interest coverage-1.69x
Cash quality & payout
Operating cash flow / net income0.36x
Accruals ratio-10.7%
Payout ratio—
Capex / revenue0.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $149.16M | $74.89M |
| Cost of revenue | $76.85M | $20.73M |
| Gross profit | $72.31M | $54.16M |
| R&D expense | $6.58M | $12.77M |
| SG&A expense | $49.70M | $30.32M |
| Operating income | -$31.44M | -$34.56M |
| Interest expense | $8.41M | $7.29M |
| Net income | -$39.00M | -$43.71M |
| EBITDA | -$27.97M | -$32.49M |
| EPS (basic) | -0.59 | -1.38 |
| EPS (diluted) | -0.59 | -1.38 |
| Weighted avg. shares (diluted) | 65.95M | 31.73M |
| Balance sheet | ||
| Cash & equivalents | $28.13M | $19.46M |
| Receivables | $16.47M | $23.36M |
| Inventory | $4.33M | $4.25M |
| Current assets | $61.55M | $58.12M |
| PP&E, net | $4.47M | $6.24M |
| Goodwill | $23.62M | $18.63M |
| Intangibles | $18.15M | $19.61M |
| Total assets | $141.55M | $140.90M |
| Current liabilities | $30.52M | $31.27M |
| Long-term debt | $65.81M | $55.15M |
| Total debt | $65.81M | $55.15M |
| Total liabilities | $115.31M | $109.10M |
| Shareholders' equity | $22.38M | $27.71M |
| Net debt | $37.67M | $35.69M |
| Shares outstanding | 68.99M | 55.68M |
| Cash flow statement | ||
| Operating cash flow | -$20.37M | -$31.00M |
| Capital expenditure | $801,000 | $1.47M |
| Free cash flow | -$21.18M | -$32.46M |
| Investing cash flow | -$801,000 | -$2.41M |
| Financing cash flow | $35.85M | -$6.81M |
| Depreciation & amortization | $3.46M | $2.07M |
| Stock-based compensation | $6.85M | $5.60M |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.